doi:10.3969/j.issn.1004-583X.2022.10.015

Abstract

CLC Number:

R587.1

Add to citation manager EndNote|Ris|BibTeX

URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2022.10.015

https://huicui.hebmu.edu.cn/EN/Y2022/V37/I10/953

References 36

[1]	Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045[J]. Diabetes Res Clin Pract, 2022, 183: 109119. doi: 10.1016/j.diabres.2021.109119 URL
[2]	Wu H, Tremaroli V, Schmidt C, et al. The gut microbiota in prediabetes and diabetes: A population-based cross-sectional study[J]. Cell Metab, 2020, 32(3):379-390.e3. doi: S1550-4131(20)30312-0 pmid: 32652044
[3]	Wei S, Brejnrod AD, Trivedi U, et al. Impact of intensive lifestyle intervention on gut microbiota composition in type 2 diabetes: A post-hoc analysis of a randomized clinical trial[J]. Gut Microbes, 2022, 14(1): 2005407. doi: 10.1080/19490976.2021.2005407 URL
[4]	Vatanen T, Franzosa EA, Schwager R, et al. The human gut microbiome in early-onset type 1 diabetes from the TEDDY study[J]. Nature, 2018, 562(7728): 589-594. doi: 10.1038/s41586-018-0620-2 URL
[5]	Gou W, Ling CW, He Y, et al. Interpretable machine learning framework reveals robust gut microbiome features associated with type 2 diabetes[J]. Diabetes Care, 2021, 44(2): 358-366. doi: 10.2337/dc20-1536 pmid: 33288652
[6]	Cunningham AL, Stephens JW, Harris DA. Gut microbiota influence in type 2 diabetes mellitus (T2DM)[J]. Gut Pathog, 2021, 13(1): 50. doi: 10.1186/s13099-021-00446-0 pmid: 34362432
[7]	Jovel J, Patterson J, Wang W, et al. Characterization of the gut microbiome using 16s or shotgun metagenomics[J]. Front Microbiol, 2016, 7: 459. doi: 10.3389/fmicb.2016.00459 pmid: 27148170
[8]	Schloissnig S, Arumugam M, Sunagawa S, et al. Genomic variation landscape of the human gut microbiome[J]. Nature, 2013, 493(7430): 45-50. doi: 10.1038/nature11711 URL
[9]	Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora[J]. Science, 2005, 308(5728): 1635-1638. doi: 10.1126/science.1110591 pmid: 15831718
[10]	Sonnenburg JL, Bäckhed F. Diet-microbiota interactions as moderators of human metabolism[J]. Nature, 2016, 535(7610): 56-64. doi: 10.1038/nature18846 URL
[11]	Reitmeier S, Kiessling S, Clavel T, et al. Arrhythmic gut microbiome signatures predict risk of type 2 diabetes[J]. Cell Host Microbe, 2020, 28(2):258-272.e6. doi: S1931-3128(20)30343-7 pmid: 32619440
[12]	Murri M, Leiva I, Gomez-Zumaquero JM, et al. Gut microbiota in children with type 1 diabetes differs from that in healthy children: A case-control study[J]. BMC Med, 2013, 11: 46. doi: 10.1186/1741-7015-11-46 pmid: 23433344
[13]	Mokhtari P, Metos J, Anandh Babu PV. Impact of type 1 diabetes on the composition and functional potential of gut microbiome in children and adolescents: Possible mechanisms, current knowledge, and challenges[J]. Gut Microbes, 2021, 13(1):1-18.
[14]	Gurung M, Li Z, You H, et al. Role of gut microbiota in type 2 diabetes pathophysiology[J]. EBio Medicine, 2020, 51: 102590.
[15]	Ho J, Nicolucci AC, Virtanen H, et al. Effect of prebiotic on microbiota, intestinal permeability, and glycemic control in children with type 1 diabetes[J]. J Clin Endocrinol Metab, 2019, 104(10): 4427-4440. doi: 10.1210/jc.2019-00481 pmid: 31188437
[16]	Groele L, Szajewska H, Szalecki M, et al. Lack of effect of GG and Bb12 on beta-cell function in children with newly diagnosed type 1 diabetes: A randomised controlled trial[J]. BMJ Open Diabetes Res Care, 2021, 9(1):e001523. doi: 10.1136/bmjdrc-2020-001523 URL
[17]	Zare Javid A, Aminzadeh M, Haghighi-Zadeh MH, et al. The effects of synbiotic supplementation on glycemic status, lipid profile, and biomarkers of oxidative stress in type 1 diabetic patients. A placebo-controlled, double-blind, randomized clinical trial[J]. Diabetes Metab Syndr Obes, 2020, 13: 607-617. doi: 10.2147/DMSO.S238867 URL
[18]	Zhao L, Zhang F, Ding X, et al. Gut bacteria selectively promoted by dietary fibers alleviate type 2 diabetes[J]. Science, 2018, 359(6380): 1151-1156. doi: 10.1126/science.aao5774 pmid: 29590046
[19]	Zhang Y, Gu Y, Ren H, et al. Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study)[J]. Nat Commun, 2020, 11(1): 5015. doi: 10.1038/s41467-020-18414-8 pmid: 33024120
[20]	Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study[J]. Nat Med, 2019, 25(7): 1096-1103. doi: 10.1038/s41591-019-0495-2 pmid: 31263284
[21]	Kanazawa A, Aida M, Yoshida Y, et al. Effects of synbiotic supplementation on chronic inflammation and the gut microbiota in obese patients with type 2 diabetes mellitus: A randomized controlled study[J]. Nutrients, 2021, 13(2):558. doi: 10.3390/nu13020558 URL
[22]	Palacios T, Vitetta L, Coulson S, et al. Targeting the intestinal microbiota to prevent type 2 diabetes and enhance the effect of metformin on glycaemia: A randomised controlled pilot study[J]. Nutrients, 2020, 12(7):2041. doi: 10.3390/nu12072041 URL
[23]	Liu L, Chen Y, Wu Q, et al. Sodium butyrate attenuated diabetes-induced intestinal inflammation by modulating gut microbiota[J]. Evid Based Complement Alternat Med, 2022, 2022: 4646245.
[24]	Mariño E, Richards JL, Mcleod KH, et al. Gut microbial metabolites limit the frequency of autoimmune T cells and protect against type 1 diabetes[J]. Nat Immunol, 2017, 18(5): 552-562. doi: 10.1038/ni.3713 pmid: 28346408
[25]	Guo Y, Xiao Z, Wang Y, et al. Sodium butyrate ameliorates streptozotocin-induced type 1 diabetes in mice by inhibiting the HMGB1 expression[J]. Front Endocrinol (Lausanne), 2018, 9: 630. doi: 10.3389/fendo.2018.00630 URL
[26]	De Groot PF, Nikolic T, Imangaliyev S, et al. Oral butyrate does not affect innate immunity and islet autoimmunity in individuals with longstanding type 1 diabetes: A randomised controlled trial[J]. Diabetologia, 2020, 63(3): 597-610. doi: 10.1007/s00125-019-05073-8 pmid: 31915895
[27]	Matheus VA, Monteiro L, Oliveira RB, et al. Butyrate reduces high-fat diet-induced metabolic alterations, hepatic steatosis and pancreatic beta cell and intestinal barrier dysfunctions in prediabetic mice[J]. Exp Biol Med (Maywood), 2017, 242(12): 1214-1226. doi: 10.1177/1535370217708188 pmid: 28504618
[28]	Roshanravan N, Mahdavi R, Alizadeh E, et al. Effect of butyrate and inulin supplementation on glycemic status, lipid profile and glucagon-like peptide 1 level in patients with type 2 diabetes: A randomized double-blind, placebo-controlled trial[J]. Horm Metab Res, 2017, 49(11): 886-891. doi: 10.1055/s-0043-119089 pmid: 28962046
[29]	Khosravi Z, Hadi A, Tutunchi H, et al. The effects of butyrate supplementation on glycemic control, lipid profile, blood pressure, nitric oxide level and glutathione peroxidase activity in type 2 diabetic patients: A randomized triple -blind, placebo-controlled trial[J]. Clin Nutr ESPEN, 2022, 49: 79-85. doi: 10.1016/j.clnesp.2022.03.008 pmid: 35623879
[30]	De Groot P, Nikolic T, Pellegrini S, et al. Faecal microbiota transplantation halts progression of human new-onset type 1 diabetes in a randomised controlled trial[J]. Gut, 2021, 70(1):92-105. doi: 10.1136/gutjnl-2020-322630 pmid: 33106354
[31]	Xie YC, Jing XB, Chen X, et al. Fecal microbiota transplantation treatment for type 1 diabetes mellitus with malnutrition: A case report[J]. Ther Adv Chronic Dis, 2022, 13: 20406223221117449.
[32]	He L, Chen R, Zhang B, et al. Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes mellitus[J]. Front Immunol, 2022, 13: 930872. doi: 10.3389/fimmu.2022.930872 URL
[33]	Wang H, Lu Y, Yan Y, et al. Promising treatment for type 2 diabetes: Fecal microbiota transplantation reverses insulin resistance and impaired islets[J]. Front Cell Infect Microbiol, 2019, 9: 455. doi: 10.3389/fcimb.2019.00455 URL
[34]	Su L, Hong Z, Zhou T, et al. Health improvements of type 2 diabetic patients through diet and diet plus fecal microbiota transplantation[J]. Sci Rep, 2022, 12(1): 1152. doi: 10.1038/s41598-022-05127-9 pmid: 35064189
[35]	Ding D, Yong H, You N, et al. Prospective study reveals host microbial determinants of clinical response to fecal microbiota transplant therapy in type 2 diabetes patients[J]. Front Cell Infect Microbiol, 2022, 12: 820367. doi: 10.3389/fcimb.2022.820367 URL
[36]	Ng SC, Xu Z, Mak JWY, et al. Microbiota engraftment after faecal microbiota transplantation in obese subjects with type 2 diabetes: A 24-week, double-blind, randomised controlled trial[J]. Gut, 2022, 71(4): 716-723. doi: 10.1136/gutjnl-2020-323617 URL

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References 36

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Lv Shasha, Song Jinlan, Shi Jian. Mitochondrial mutation m.3243A> G associated with diabetes mellitus: One case report and literature review [J]. Clinical Focus, 2024, 39(2): 160-163.
[2]	Zhang Jianan, Sun Linlin, Zhan Xiaoyan, Li Bing. Correlation between serum Vitamin B₁₂ and mild cognitive impairment in elderly patients with type 2 diabetes mellitus [J]. Clinical Focus, 2024, 39(1): 34-37.
[3]	Liao Kunfeng, Yao Yisong, Yang Jinpan, Yang Xining, Li Yaru, Zhou Hongyan, Liang Piao. Status and influencing factors of fear of progression in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(12): 1095-1100.
[4]	Shi Peihua, Lin Yanlin, Bi Lifang. Study on the correlation of NLR, PLR and MLR with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2023, 38(11): 996-1001.
[5]	Yang Xin, Xu Huajiao. Bibliometric analysis of literatures reporting psychological intervention of patients with diabetes mellitus: Based on Web of Science [J]. Clinical Focus, 2023, 38(8): 731-736.
[6]	Jin Jiahui, Yang Yang, Qin Tong, He Yuxin, Su Meihua. Probiotic supplementation on improving glucose metabolism in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(7): 581-587.
[7]	Wu Yanan, Yan Tianmei, Liang Peng, Wei Limin. High-risk identification of depressive symptoms in middle-elderly patients with diabetes [J]. Clinical Focus, 2023, 38(6): 516-520.
[8]	Yang Minxing, Sun Lu, Ye Yun, Xu Wendong, Huang Xiaolin, Zhang Haiyun, Xu Yinglei. Characteristics of cognitive function and corresponding factors in young and middle-aged patients with type 2 diabetes with obstructive sleep apnea hypopnea syndrome [J]. Clinical Focus, 2023, 38(3): 216-220.
[9]	Rao Xiaojuan, Shi Shuangwei, Sang Yanhong. Comparison of short-term efficacy of insulin degludec/insulin versus continuous subcutaneous infusion of insulin asparton diabetic patients admitted in non-endocrinology departments [J]. Clinical Focus, 2023, 38(2): 132-136.
[10]	Xie Feifei, Zhang Weijian. Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A meta-analysis [J]. Clinical Focus, 2023, 38(1): 20-36.
[11]	Wang Cui, Lin Hao, Wu Pingping, Zhang Yali, Ren Jian, Xu Ting, Dong Guoyu, Zai Guotian. Correlation between hyperhomocysteinemia and early renal disease in patients with type 2 diabetes mellitus [J]. Clinical Focus, 2023, 38(1): 42-45.
[12]	. [J]. Clinical Focus, 2023, 38(1): 79-83.
[13]	Wang Runqing, Wang Qian, Liao Jianxiong. A network meta-analysis of SGLT2 inhibitors on cardiovascular outcomes in patients with type 2 diabetes [J]. Clinical Focus, 2022, 37(12): 1061-1073.
[14]	Wang Wenqi, Zhang Tao. Effect of semaglutide on total myocardial ischemic burden and serum inflammatory factors in patients with type 2 diabetes mellitus complicated with coronary heart disease [J]. Clinical Focus, 2022, 37(11): 996-1000.
[15]	Zhao Liyan, Kang wei, Wang Qingzhou, Li Bopeng, Cao Yawei, Li Junfen, Shao Liang, Wang Kang. Correlation analysis between lipid accumulation index and visceral fat index and glucose metabolism disorders in first-degree relatives of type 2 diabetes mellitus [J]. Clinical Focus, 2022, 37(9): 804-807.